Anal Squamous Cell Carcinoma

Quick Answer

Anal squamous cell carcinoma is FDG-avid, and PET/CT is well suited to its two key questions: nodal staging — especially the inguinal and pelvic nodes whose involvement changes the radiotherapy field — and radiotherapy planning and post-chemoradiation response. Because the standard of care is definitive chemoradiation (organ-preserving), not upfront surgery, accurate nodal mapping and response assessment matter enormously, and FDG frequently upstages nodal disease over CT alone. Response is judged on timing-appropriate follow-up imaging, since post-radiation inflammation is avid early.

Where FDG changes management

The decisive contribution is nodal staging that defines the radiation field: FDG detects inguinal and pelvic nodal disease more sensitively than CT, and involved inguinal nodes must be included in the treatment volume. Because anal cancer is treated with definitive chemoradiation (surgery reserved for salvage), getting the nodal map and field right is central, and PET commonly alters the plan.

FDG-PET/CT roles: staging (primary + inguinal/pelvic nodes), radiotherapy target/field definition, and assessment of response after chemoradiation — with recurrence detection during follow-up.

Response timing

Response is assessed on appropriately timed post-treatment imaging: post-radiation inflammation of the anorectum is FDG-avid, so imaging too early causes false positives. A complete metabolic response at an adequate interval supports the organ-preserving strategy, while persistent focal uptake raises concern for residual disease and possible salvage. Correlate with clinical exam (the anal canal is directly examinable).

Common Pitfalls / Cautions

• Do not assess post-chemoradiation response too early — anorectal inflammation is FDG-avid.
• Physiologic anal/rectal and bowel activity, and hemorrhoidal/inflammatory uptake, can confound the primary site.
• Inguinal nodal involvement is field-defining — scrutinise it.

Board Pearls

• Anal SCC is HPV-associated and reliably FDG-avid; guidelines endorse PET/CT for staging because it upstages nodal disease over CT and defines the radiotherapy field.
• Standard of care is definitive chemoradiation (5-fluorouracil + mitomycin C + radiotherapy, the Nigro-type regimen); abdominoperineal resection is reserved for salvage — so imaging, not a resection specimen, drives management.
• Inguinal nodal status is field-defining: FDG-positive inguinal nodes are included in the radiation volume.
• Assess treatment response on appropriately delayed imaging (typically several months after chemoradiation) — earlier scans are confounded by avid post-radiation inflammation.
• A complete metabolic response at an adequate interval predicts better outcome; persistent or progressive focal uptake prompts biopsy and consideration of salvage surgery.

Differential Diagnosis

Causes of FDG uptake in the anal/perianal region that can mimic or obscure tumour:

• Physiologic anorectal and bowel activity — usually diffuse and symmetric.
• Benign inflammatory uptake — hemorrhoids, proctitis, fistula-in-ano, or perianal abscess.
• Post-radiation inflammation — timing-dependent; a common cause of a false-positive "residual disease" read.
• Anal adenocarcinoma (vs squamous) — histology and management differ; correlate with biopsy.
• Anal condyloma / low-grade HPV lesions — can be mildly avid.

Reporting Checklist

• Primary tumour: location within the anal canal/margin, size, and SUVmax.
• Nodal status by station: perirectal/mesorectal, internal and external iliac, and — stated explicitly — inguinal nodes (field-defining).
• Distant disease: para-aortic nodes, liver, lung, bone.
• Response studies: state the interval since chemoradiation completion, classify as complete vs partial metabolic response, and flag any new or persistent focal uptake with a clear recommendation (short-interval follow-up, biopsy, or salvage referral).
• Correlation: reconcile findings with the clinical/anorectal exam, which is directly accessible.

Self-Check

Key References

• Society guidance and cohorts on FDG-PET/CT for staging, radiotherapy planning, and response in anal squamous cell carcinoma.
• Literature on inguinal nodal detection altering radiation fields and on response-assessment timing after chemoradiation.